Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis (Review)
- Authors:
- Muhammad Shahid
- Austin Yeon
- Jayoung Kim
-
Affiliations: Department of Surgery, Cedars‑Sinai Medical Center, Los Angeles, CA 90048, USA - Published online on: October 22, 2020 https://doi.org/10.3892/mmr.2020.11627
- Pages: 5003-5011
-
Copyright: © Shahid et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Sjodahl G, Lauss M, Lovgren K, Chebil G, Gudjonsson S, Veerla S, Patschan O, Aine M, Fernö M, Ringnér M, et al: A molecular taxonomy for urothelial carcinoma. Clin Cancer Res. 18:3377–3386. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
European Association of Urology (EAU), . EAU Guidelines on Urological Infections. EAU Guidelines Office; Arnhem: 2018, simplehttps://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Urological-Infections-2018-large-text.pdf | |
|
Czerniak B, Dinney C and McConkey D: Origins of bladder cancer. Annu Rev Pathol. 11:149–174. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Gruber K: Coffee consumption and bladder cancer are linked, analysis shows. BMJ. 350:h14772015. View Article : Google Scholar : PubMed/NCBI | |
|
Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Maleki Vareki S, Pal SK and Sfanos KS: The microbiome and genitourinary cancer: A collaborative review. Eur Urol. 75:637–646. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Knowles MA and Hurst CD: Molecular biology of bladder cancer: New insights into pathogenesis and clinical diversity. Nat Rev Cancer. 15:25–41. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Q, Su M, Lu G and Wang J: The complexity of bladder cancer: Long noncoding RNAs are on the stage. Mol Cancer. 12:1012013. View Article : Google Scholar : PubMed/NCBI | |
|
Chen M, Li J, Zhuang C and Cai Z: Increased lncRNA ABHD11-AS1 represses the malignant phenotypes of bladder cancer. Oncotarget. 8:28176–28186. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chen M, Zhuang C, Liu Y, Li J, Dai F, Xia M, Zhan Y, Lin J, Chen Z, He A, et al: Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Cancer Lett. 376:155–164. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR and Cheng L: Variants and new entities of bladder cancer. Histopathology. 74:77–96. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB and Schmitz-Dräger BJ: New horizons in bladder cancer research. Urol Oncol. March 7–2019.(Epub ahead of print). View Article : Google Scholar | |
|
Kim S, Kim Y, Kong J, Kim E, Choi JH, Yuk HD, Lee H, Kim HR, Lee KH, Kang M, et al: Epigenetic regulation of mammalian Hedgehog signaling to the stroma determines the molecular subtype of bladder cancer. Elife. 8:e430242019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen LM, Chang M, Dai Y, Chai KX, Dyrskjøt L, Sanchez-Carbayo M, Szarvas T, Zwarthoff EC, Lokeshwar V, Jeronimo C, et al: External validation of a multiplex urinary protein panel for the detection of bladder cancer in a multicenter cohort. Cancer Epidemiol Biomarkers Prev. 23:1804–1812. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Loras A, Suarez-Cabrera C, Martinez-Bisbal MC, Quintás G, Paramio JM, Martínez-Máñez R, Gil S and Ruiz-Cerdá JL: Integrative metabolomic and transcriptomic analysis for the study of bladder cancer. Cancers (Basel). 11:6862019. View Article : Google Scholar | |
|
Sjodahl G, Jackson CL, Bartlett JM, Siemens DR and Berman DM: Molecular profiling in muscle-invasive bladder cancer: More than the sum of its parts. J Pathol. 247:563–573. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, Yeh JJ, Milowsky MI, Iyer G, Parker JS and Kim WY: Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci USA. 111:3110–3115. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al: Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 25:152–165. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Cancer Genome Atlas Research Network, . Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, et al: Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 174:10332018. View Article : Google Scholar : PubMed/NCBI | |
|
Davis NF, Brady CM and Creagh T: Interstitial cystitis/painful bladder syndrome: Epidemiology, pathophysiology and evidence-based treatment options. Eur J Obstet Gynecol Reprod Biol. 175:30–37. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Fall M, Baranowski AP, Elneil S, Engeler D, Hughes J, Messelink EJ, Oberpenning F and de C Williams AC; European Association of Urology, : EAU guidelines on chronic pelvic pain. Eur Urol. 57:35–48. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Hanno P, Lin A, Nordling J, van Ophoven A, Ueda T and Wein A; Bladder Pain Syndrome Committee of the International Consultation on Incontinence, : Bladder pain syndrome committee of the international consultation on incontinence. Neurourol Urodyn. 29:191–198. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Clemens JQ, Mullins C, Ackerman AL, Bavendam T, van Bokhoven A, Ellingson BM, Harte SE, Kutch JJ, Lai HH, Martucci KT, et al: Urologic chronic pelvic pain syndrome: Insights from the MAPP research network. Nat Rev Urol. 16:187–200. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
van de Merwe JP, Nordling J, Bouchelouche P, Bouchelouche K, Cervigni M, Daha LK, Elneil S, Fall M, Hohlbrugger G, Irwin P, et al: Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: An ESSIC proposal. Eur Urol. 53:60–67. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, Fitzgerald MP, Forrest JB, Gordon B, Gray M, Mayer RD, et al: AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 185:2162–2170. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Akiyama Y, Maeda D, Katoh H, Morikawa T, Niimi A, Nomiya A, Sato Y, Kawai T, Goto A, Fujimura T, et al: Molecular taxonomy of interstitial cystitis/bladder pain syndrome based on whole transcriptome profiling by next-generation RNA sequencing of bladder mucosal biopsies. J Urol. 202:290–300. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Peters KM, Killinger KA, Mounayer MH and Boura JA: Are ulcerative and nonulcerative interstitial cystitis/painful bladder syndrome 2 distinct diseases? A study of coexisting conditions. Urology. 78:301–308. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Seyhan AA and Carini C: Are innovation and new technologies in precision medicine paving a new era in patients centric care? J Transl Med. 17:1142019. View Article : Google Scholar : PubMed/NCBI | |
|
Clish CB: Metabolomics: An emerging but powerful tool for precision medicine. Cold Spring Harb Mol Case Stud. 1:a0005882015. View Article : Google Scholar : PubMed/NCBI | |
|
Kuehnbaum NL and Britz-McKibbin P: New advances in separation science for metabolomics: Resolving chemical diversity in a post-genomic era. Chem Rev. 113:2437–2468. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Griffin JL and Shockcor JP: Metabolic profiles of cancer cells. Nat Rev Cancer. 4:551–561. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Vander Heiden MG: Targeting cancer metabolism: A therapeutic window opens. Nat Rev Drug Discov. 10:671–684. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Pereira MM, Shori DK, Dormer RL and McPherson MA: Studies on phosphorylation of calcineurin. Biochem Soc Trans. 18:4471990. View Article : Google Scholar : PubMed/NCBI | |
|
Gatenby RA and Gillies RJ: Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 4:891–899. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Han X: Lipidomics for studying metabolism. Nat Rev Endocrinol. 12:668–679. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lydic TA and Goo YH: Lipidomics unveils the complexity of the lipidome in metabolic diseases. Clin Transl Med. 7:42018. View Article : Google Scholar : PubMed/NCBI | |
|
Blanksby SJ and Mitchell TW: Advances in mass spectrometry for lipidomics. Annu Rev Anal Chem (Palo Alto Calif). 3:433–465. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Emwas AH, Roy R, McKay RT, Tenori L, Saccenti E, Gowda GAN, Raftery D, Alahmari F, Jaremko L, Jaremko M and Wishart DS: NMR spectroscopy for metabolomics research. Metabolites. 9:1232019. View Article : Google Scholar | |
|
Fiehn O and Kim J: Metabolomics insights into pathophysiological mechanisms of interstitial cystitis. Int Neurourol J. 18:106–114. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Chen Z and Kim J: Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases. BMC Urol. 16:112016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu CZ, Ting HN, Ng KH and Ong TA: A review on the accuracy of bladder cancer detection methods. J Cancer. 10:4038–4044. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kim J, Kim WT and Kim WJ: Advances in urinary biomarker discovery in urological research. Investig Clin Urol. 61 (Suppl 1):S8–S22. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Nicholson JK, Connelly J, Lindon JC and Holmes E: Metabonomics: A platform for studying drug toxicity and gene function. Nat Rev Drug Discov. 1:153–161. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, et al: Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature. 457:910–914. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jobard E, Pontoizeau C, Blaise BJ, Bachelot T, Elena-Herrmann B and Tredan O: A serum nuclear magnetic resonance-based metabolomic signature of advanced metastatic human breast cancer. Cancer Lett. 343:33–41. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Carrola J, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, Bernardo J, Gomes A, Sousa V, Carvalho L and Duarte IF: Metabolic signatures of lung cancer in biofluids: NMR-based metabonomics of urine. J Proteome Res. 10:221–230. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Chen F, Xue J, Zhou L, Wu S and Chen Z: Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem. 401:1899–1904. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Rodrigues D, Jeronimo C, Henrique R, Belo L, de Lourdes Bastos M, de Pinho PG and Carvalho M: Biomarkers in bladder cancer: A metabolomic approach using in vitro and ex vivo model systems. Int J Cancer. 139:256–268. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sahu D, Lotan Y, Wittmann B, Neri B and Hansel DE: Metabolomics analysis reveals distinct profiles of nonmuscle-invasive and muscle-invasive bladder cancer. Cancer Med. 6:2106–2120. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yumba Mpanga A, Siluk D, Jacyna J, Szerkus O, Wawrzyniak R, Markuszewski M, Matuszewski M, Kaliszan R and Markuszewski MJ: Targeted metabolomics in bladder cancer: From analytical methods development and validation towards application to clinical samples. Anal Chim Acta. 1037:188–199. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Jin X, Yun SJ, Jeong P, Kim IY, Kim WJ and Park S: Diagnosis of bladder cancer and prediction of survival by urinary metabolomics. Oncotarget. 5:1635–1645. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Yang K and Han X: Lipidomics: Techniques, applications, and outcomes related to biomedical sciences. Trends Biochem Sci. 41:954–969. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Ellis DI, Dunn WB, Griffin JL, Allwood JW and Goodacre R: Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics. 8:1243–1266. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Wang M and Han X: Applications of mass spectrometry for cellular lipid analysis. Mol Biosyst. 11:698–713. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Dill AL, Eberlin LS, Costa AB, Zheng C, Ifa DR, Cheng L, Masterson TA, Koch MO, Vitek O and Cooks RG: Multivariate statistical identification of human bladder carcinomas using ambient ionization imaging mass spectrometry. Chemistry. 17:2897–2902. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lee MY, Yeon A, Shahid M, Cho E, Sairam V, Figlin R, Kim KH and Kim J: Reprogrammed lipid metabolism in bladder cancer with cisplatin resistance. Oncotarget. 9:13231–13243. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kind T, Cho E, Park TD, Deng N, Liu Z, Lee T, Fiehn O and Kim J: Interstitial cystitis-associated urinary metabolites identified by mass-spectrometry based metabolomics analysis. Sci Rep. 6:392272016. View Article : Google Scholar : PubMed/NCBI | |
|
Clemens JQ, Mullins C, Kusek JW, Kirkali Z, Mayer EA, Rodríguez LV, Klumpp DJ, Schaeffer AJ, Kreder KJ, Buchwald D, et al: The MAPP research network: A novel study of urologic chronic pelvic pain syndromes. BMC Urol. 14:572014. View Article : Google Scholar : PubMed/NCBI | |
|
Parker KS, Crowley JR, Stephens-Shields AJ, van Bokhoven A, Lucia MS, Lai HH, Andriole GL, Hooton TM, Mullins C and Henderson JP: Urinary metabolomics identifies a molecular correlate of interstitial cystitis/bladder pain syndrome in a multidisciplinary approach to the study of chronic pelvic pain (MAPP) research network cohort. EBioMedicine. 7:167–174. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Mbeutcha A, Lucca I, Mathieu R, Lotan Y and Shariat SF: Current status of urinary biomarkers for detection and surveillance of bladder cancer. Urol Clin North Am. 43:47–62. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang WT, Zhang ZW, Guo YD, Wang LS, Mao SY, Zhang JF, Liu MN and Yao XD: Discovering biomarkers in bladder cancer by metabolomics. Biomark Med. 12:1347–1359. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo HC: Potential urine and serum biomarkers for patients with bladder pain syndrome/interstitial cystitis. Int J Urol. 21 (Suppl 1):S34–S41. 2014. View Article : Google Scholar | |
|
Srivastava S, Roy R, Singh S, Kumar P, Dalela D, Sankhwar SN, Goel A and Sonkar AA: Taurine-a possible fingerprint biomarker in non-muscle invasive bladder cancer: A pilot study by 1H NMR spectroscopy. Cancer Biomark. 6:11–20. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Anderson NM, Mucka P, Kern JG and Feng H: The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 9:216–237. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Pasikanti KK, Esuvaranathan K, Ho PC, Mahendran R, Kamaraj R, Wu QH, Chiong E and Chan EC: Noninvasive urinary metabonomic diagnosis of human bladder cancer. J Proteome Res. 9:2988–2995. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Wittmann BM, Stirdivant SM, Mitchell MW, Wulff JE, McDunn JE, Li Z, Dennis-Barrie A, Neri BP, Milburn MV, Lotan Y and Wolfert RL: Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS One. 9:e1158702014. View Article : Google Scholar : PubMed/NCBI | |
|
Shen C, Sun Z, Chen D, Su X, Jiang J, Li G, Lin B and Yan J: Developing urinary metabolomic signatures as early bladder cancer diagnostic markers. OMICS. 19:1–11. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Pasikanti KK, Esuvaranathan K, Hong Y, Ho PC, Mahendran R, Raman Nee Mani L, Chiong E and Chan EC: Urinary metabotyping of bladder cancer using two-dimensional gas chromatography time-of-flight mass spectrometry. J Proteome Res. 12:3865–3873. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Putluri N, Shojaie A, Vasu VT, Vareed SK, Nalluri S, Putluri V, Thangjam GS, Panzitt K, Tallman CT, Butler C, et al: Metabolomic profiling reveals potential markers and bioprocesses altered in bladder cancer progression. Cancer Res. 71:7376–7386. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tripathi P, Somashekar BS, Ponnusamy M, Gursky A, Dailey S, Kunju P, Lee CT, Chinnaiyan AM, Rajendiran TM and Ramamoorthy A: HR-MAS NMR tissue metabolomic signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. J Proteome Res. 12:3519–3528. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yang C, Sun X, Wang H, Lu T, Wu K, Guan Y, Tang J, Liang J, Sun R, Guo Z, et al: Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine. Int J Mol Med. 44:1952–1962. 2019.PubMed/NCBI | |
|
Cao M, Zhao L, Chen H, Xue W and Lin D: NMR-based metabolomic analysis of human bladder cancer. Anal Sci. 28:451–456. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Bansal N, Gupta A, Mitash N, Shakya PS, Mandhani A, Mahdi AA, Sankhwar SN and Mandal SK: Low- and high-grade bladder cancer determination via human serum-based metabolomics approach. J Proteome Res. 12:5839–5850. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Wen H, Lee T, You S, Park SH, Song H, Eilber KS, Anger JT, Freeman MR, Park S and Kim J: Urinary metabolite profiling combined with computational analysis predicts interstitial cystitis-associated candidate biomarkers. J Proteome Res. 14:541–548. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Fukui Y, Kato M, Inoue Y, Matsubara A and Itoh K: A metabonomic approach identifies human urinary phenylacetylglutamine as a novel marker of interstitial cystitis. J Chromatogr B Analyt Technol Biomed Life Sci. 877:3806–3812. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Lamale LM, Lutgendorf SK, Zimmerman MB and Kreder KJ: Interleukin-6, histamine, and methylhistamine as diagnostic markers for interstitial cystitis. Urology. 68:702–706. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Shahid M, Lee MY, Yeon A, Cho E, Sairam V, Valdiviez L, You S and Kim J: Menthol, a unique urinary volatile compound, is associated with chronic inflammation in interstitial cystitis. Sci Rep. 8:108592018. View Article : Google Scholar : PubMed/NCBI |
